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Summary
p63 and p73 are functionally and structurally related to the tumor suppressor p53. However, their own role in tumor
suppression is unclear. Given the p53-like properties of p63 and p73, we tested whether they are involved in tumor sup-
pression by aging mice heterozygous for mutations in all p53 family genes and scored for spontaneous tumors. We show
here that p63+/−;p73+/− mice develop spontaneous tumors. Loss of p63 and p73 can also cooperate with loss of p53 in
tumor development. Mice heterozygous for mutations in both p53 and p63 or p53 and p73 displayed higher tumor burden
and metastasis compared to p53+/− mice. These findings provide evidence for a broader role for the p53 family than has
been previously reported.S I G N I F I C A N C E
The discovery of the p53-related genes p63 and p73 raised the possibility that they may be cancer-associated genes. However,
initial reports indicated that mutations in p63 and p73 are rare in human cancers. We have found that mice that are p63+/−;p73+/−
develop malignant tumors at high frequency. In addition, p53+/−;p63+/− and p53+/−;p73+/− developed a more severe phenotype
(higher tumor burden and metastases). Using mouse models, we have shown that inactivation of p63 and p73 leads to tumor types
in the mouse frequently found to lose expression or have mutations in p63 or p73 in human tumors. This study identifies a previously
unrecognized function of these genes and supports a broader role for the p53 family in tumor suppression.Introduction
p63 and p73 were cloned due to their structural similarity to
p53. However, they have been found to be more complex than
p53 due to the existence of several variant isoforms. Both p63
and p73 contain carboxy-terminal spliced variants known as
the TA isoforms. So-called N variants also exist that lack the
transactivation domain and are transcribed from an internal
promoter within exon 3 of the full-length genes (Irwin and Kae-
lin, 2001; Yang et al., 1998). These different isoforms have been
shown to have vastly different activities. The TA isoforms act
similarly to p53. They have the ability to transactivate p53
target genes and induce apoptosis. In contrast, the N iso-
forms have little transactivation activity and are thought to play
a role in blocking transactivation of target genes of both p53
and their respective TA isoforms (Yang et al., 2002). Therefore,
the TA isoforms might be expected to have a role in tumor
suppression, while increased expression of the N isoforms
might be oncogenic.
Gene targeting studies in the mouse have revealed that both
p63 and p73 have roles in normal development (Mills et al.,CANCER CELL : APRIL 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INC1999; Yang et al., 1999; Yang et al., 2000). The mutations de-
lete the central DNA binding domain of p63 and p73 and, thus,
affect all isoforms of the genes. p63-deficient mice are born
with craniofacial abnormalities, limb truncations, and a thin
layer of undifferentiated skin. They die within hours after birth
due to desiccation and maternal neglect (Mills et al., 1999;
Yang et al., 1999). p73 mutant mice also survive to birth but
are runted and have hydrocephalus as well as hippocampal
dysgenesis. The majority of p73-deficient mice live to be only
4 to 6 weeks old and die due to chronic infections (Yang et al.,
2000). In our colony, approximately 25% survive to adulthood.
Because of the complexity of the p63 and p73 loci and the lack
of a detailed characterization of the molecular effects of the
targeted mutations, it is possible that the mutant alleles might
still produce truncated mRNAs and proteins that could compli-
cate the interpretation of the mutant phenotypes.
The literature on p63 and p73 is complex and controversial,
and their role in tumor suppression has been much debated.
In studies performed to date, only a small percentage of human
tumors have been shown to harbor p63 and p73 mutations
(Irwin and Kaelin, 2001). However, recent studies have shown. DOI 10.1016/j.ccr.2005.02.019 363
A R T I C L Ethat p63 and p73 have tumor-suppressive activities in human
tumors. While some studies have shown overexpression of
some isoforms of p63 or p73 in human tumors (Hibi et al.,
2000; Nozaki et al., 2001), certain tumor types (transitional cell
carcinomas, mammary adenocarcinomas, squamous cell car-
cinomas, and osteosarcomas) exhibit loss or reduced expres-
sion of p63 and/or p73 (Ahomadegbe et al., 2000; Koga et al.,
2003; Park et al., 2000; Park et al., 2004; Puig et al., 2003; Urist
et al., 2002). However, these studies have been complicated by
the lack of antibodies that distinguish between the TA and N
isoforms. More recent studies using antibodies or RT-PCR for
specific isoforms of p63 or p73 have shown increased or de-
creased expression of the TA or N isoforms of p63 and p73.
The few studies on human tumors that have been performed
to date to determine the significance of the TA versus N iso-
forms have shown that some tumors do specifically lose TA
isoform expression (Park et al., 2000), while others have in-
creased expression of the N isoforms (Concin et al., 2004;
Moll, 2003; Zaika et al., 2002). In addition to loss of expression
of p63 in some human tumors, 12% of chronic myelogenous
leukemias examined were found to have mutations in p63 (Ya-
maguchi et al., 2001) contributing to the evidence that p63 has
tumor-suppressive activities. Many more studies using anti-
bodies or RT-PCR for specific isoforms must be performed in
additional human tumors to determine the significance of the
loss or gain of each isoform.
To date, a systematic analysis of tumor development in mice
that are mutant for p63 and p73 has not been performed, and
the synergistic effects of the p53 family in tumor suppression
have not been examined. The present study examines the
long-term tumorigenic effects of p63 and p73 mutation, alone
or in combination with p53. The data support a model whereby
p63 and p73 play an important role in tumor suppression in
specific tissues in the mouse.
Results
p63 or p73 mutation leads to tumor predisposition
in the mouse
The p63 and p73 mutant mice used in this study carry muta-
tions that remove a large segment of the central DNA binding
domain that are thought to inactivate all of the isoforms of
these genes (Mills et al., 1999; Yang et al., 1999; Yang et al.,
2000). Due to the complexity of these loci, it remains possible
the mutant alleles produce truncated products; however, for
simplicity, we have referred to the mutant alleles here as p63−/−
and p73−/−. To determine if p63 or p73 mutation alone could
cause tumor predisposition, a large cohort of p63 and p73 het-
erozygous mice (p63+/− and p73+/−) were aged for two years
or until moribund. Both groups (consisting of 40 mice) for each
genotype had a shortened life span compared to their wild-
type littermates (Figure 1). By 14 to 15 months of age, half
of the p63+/− and p73+/− mice were moribund and had to be
euthanized. Statistical analysis was performed using a log-rank
test. The survival time of p63+/− and p73+/− mice was found to
be statistically significant compared to the time of survival of
wild-type mice, with a p value of 0.0001 for both. After two
years, 32 out of 40 p63+/− mice and 36 out of 40 p73+/− mice
had been sacrificed or died, compared to 8 out of 40 in the
wild-type group. All animals in this study were subjected to full364Figure 1. Kaplan-Meier survival curves of wild-type, p53+/−, p63+/−, p73+/−,
p53+/−;p63+/−, p53+/−;p73+/−, and p63+/−;p73+/− mice showing the fraction of
mice alive up to 24 months
Genotypes are color-coded. The median time of survival was 10 months for
p53+/−, 15 months for p63+/−, 14 months for p73+/−, 7 months for p53+/−;p63+/−,
6 months for p53+/−;p73+/−, and 8 months for p63+/−;p73+/− mice. The log-
rank test was performed to determine the statistical significance between
the survival time of wild-type and p63+/− or p73+/− mice (p = 0.0001 for
both), the difference between the survival time of p63+/− or p73+/− and
p63+/−;p73+/− mice (p = 0.0001 for both), and the difference between the
survival time of p53+/− and p53+/−;p63+/− or p53+/−;p73+/− mice (p = 0.001 and
p = 0.0004, respectively).necropsy to determine the frequency and spectrum of sponta-
neous tumor formation.
Strikingly, p63+/− and p73+/− mice developed malignant lesions,
demonstrating that these genes can act as tumor suppressors. Ten
percent of p63+/− mice (n = 40 total mice examined) developed
squamous cell carcinomas, and 20% developed histiocytic sar-
comas by 12 months of age (Table 1). Ten percent of p73+/− mice
developed lung adenocarcinomas, while 12.5% percent devel-
oped thymic lymphoma and 12.5% had hemangiosarcomas
(Table 1). In addition to these malignant lesions, heterozygous
mutant mice showed an increase in benign premalignant
lesions, such as squamous cell hyperplasia and multiple lung
adenomas. The frequency of lung adenomas in p63+/− and
p73+/− was 2.5 and 4 times that seen in wild-type mice, respec-
tively (Table 1). While not all of the mice developed malignant
lesions, the remaining mice died from complications due to the
benign lesions. For example, in p63+/− and p73+/− mice, many
died due to obstructed airways from hyperplastic or premalig-
nant lesions in the pharynx, larynx, mouth, or tongue. In addi-
tion to analyzing heterozygous mice for p73, a group of 40
p73−/− mice were aged until moribund. As reported previously,
many of them died due to chronic infections at approximately
4 to 5 weeks of age (Yang et al., 2000). We were able to monitor
10 out of 40 to the age of 10 months. Six out of those 10
developed lung adenocarcinomas, indicating that loss of p73
in this tissue leads to tumor formation (Table 1).
Tumors from p63+/− and p73+/− mice undergo loss
of heterozygosity (LOH)
LOH is one of the hallmarks of tumor suppressor gene inactiva-
tion in cancer (Knudson, 1975; Knudson, 1986). To determine
if the tumors in the p63+/− or p73+/− mice lose the wild-typeCANCER CELL : APRIL 2005
A R T I C L ETable 1. Tumor spectrum of mice mutant for the p53 family members
Tumor type Genotype % mice (n = 40) Tumor type Genotype % mice (n = 40)
Mammary adenocarcinoma wild-type 0% Osteosarcoma p73+/− 0%
p53+/− 0% p53+/−p63+/− 20%
p63+/− 0% p53+/−;p73+/− 20%
p73+/− 0% p63+/−;p73+/− 20%
p53+/−;p63+/− 10% Hepatocellular carcinoma wild-type 0%
p53+/−;p73+/− 0% p53+/− 0%
p63+/−;p73+/− 20% p63+/− 0%
Lung adenoma wild-type 10% p73+/− 0%
p53+/− 0% p53+/−;p63+/− 0%
p63+/− 25% p53+/−;p73+/− 15%
p73+/− 40% p63+/−;p73+/− 0%
p53+/−;p63+/− 0% Transitional cell carcinoma wild-type 0%
p53+/−;p73+/− 0% p53+/− 0%
p63+/−;p73+/− 0% p63+/− 0%
Lung adenocarcinoma wild-type 0% p73+/− 0%
p53+/− 0% p53+/−;p63+/− 20%
p63+/− 0% p53+/−;p73+/− 0%
p73+/− 10% p63+/−;p73+/− 0%
p53+/−;p63+/− 0% Myelogenous leukemia wild-type 0%
p53+/−;p73+/− 10% p53+/− 0%
p63+/−;p73+/− 15% p63+/− 0%
*p73−/− 60% (n = 10 mice) p73+/− 0%
Salivary adenoma wild-type 0% p53+/−;p63+/− 15%
p53+/− 0% p53+/−;p73+/− 0%
p63+/− 0% p63+/−;p73+/− 10%
p73+/− 0% Thymic lymphoma wild-type 0%
p53+/−;p63+/− 0% p53+/− 20%
p53+/−;p73+/− 0% p63+/− 0%
p63+/−;p73+/− 25% p73+/− 12.5%
Squamous cell hyperplasia wild-type 5% p53+/−;p63+/− 10%
p53+/− 0% p53+/−;p73+/− 22.5%
p63+/− 50% p63+/−;p73+/− 10%
p73+/− 30% Histiocytic sarcoma wild-type 0%
p53+/−;p63+/− 0% p53+/− 22.5%
p53+/−;p73+/− 0% p63+/− 20%
p63+/−;p73+/− 20% p73+/− 0%
Squamous cell carcinoma wild-type 0% p53+/−;p63+/− 0%
p53+/− 0% p53+/−;p73+/− 0%
p63+/− 10% p63+/−;p73+/− 0%
p73+/− 0% Hemangiosarcoma wild-type 0%
p53+/−;p63+/− 50% p53+/− 15%
p53+/−;p73+/− 0% p63+/− 0%
p63+/−;p73+/− 30% p73+/− 12.5%
Acinar pancreatic carcinoma wild-type 0% p53+/−;p63+/− 0%
p53+/− 0% p53+/−;p73+/− 10%
p63+/− 0% p63+/−;p73+/− 5%
p73+/− 0% Rhabdomyosarcoma wild-type 0%
p53+/−;p63+/− 0% p53+/− 20%
p53+/−;p73+/− 15% p63+/− 0%
p63+/−;p73+/− 0% p73+/− 0%
Osteosarcoma wild-type 0% p53+/−;p63+/− 20%
p53+/− 22.5% p53+/−;p73+/− 20%
p63+/− 0% p63+/−;p73+/− 20%allele of the respective genes, DNA was extracted from tumors
that were macroscopically visible, and analyzed by Southern
blotting. Microscopic tumors were analyzed using laser capture
microdissection followed by PCR. As shown in Table 2, a high
percentage of tumors in the p63+/− and p73+/− mice exhibited
loss of the remaining wild-type allele (see Table 2 for full sum-
mary of LOH data). For example, in all 5 of the squamous cell
carcinomas (SCC) (Figure 2B [T7]) and 7 of the 10 histiocytic
sarcomas from p63+/− mice, loss of the wild-type copy of p63
was observed (Table 2). Likewise, 8 of 10 thymic lymphomas
and 4 of 5 lung adenocarcinomas and hemangiosarcomas inCANCER CELL : APRIL 2005p73+/− tumors exhibited LOH (Table 2 and Figure 2D [T10]).
These data strongly support the tumor suppressive functions
of p63 and p73 and establish a tumor cell autonomous effect
for their mutation in tumor development.
Mice mutant for both p63 and p73 exhibit a complex
tumor phenotype
To examine whether p63 and p73might have overlapping func-
tions related to tumor suppression, we intercrossed mice het-
erozygous for p63 and p73 to obtain mice that were heterozy-
gous for mutations in both genes (p63+/−;p73+/−) (n = 40 mice).365
A R T I C L ETable 2. Tumors derived from mice mutant for the p53 family of genes exhibit LOH
Genotype Tumor p53 p63 p73 Combined
p53+/− thymic lymphoma, n = 10 90% N/A N/A N/A
histiocytic sarcoma, n = 5 80% N/A N/A N/A
rhabdomyosarcoma, n = 5 80% N/A N/A N/A
osteosarcoma, n = 5 80% N/A N/A N/A
hemangiosarcoma, n = 5 80% N/A N/A N/A
p63+/− histicytic sarcoma, n = 10 N/A 70% N/A N/A
squamous cell carcinoma, n = 5 N/A 100% N/A N/A
lung adenoma, n = 5 N/A 60% N/A N/A
p73+/− thymic lymphoma, n = 10 N/A N/A 80% N/A
lung adenoma, n = 5 N/A N/A 100% N/A
lung adenocarcinoma, n = 5 N/A N/A 80% N/A
hemangiosarcoma, n = 5 N/A N/A 80% N/A
p53+/−;p63+/− transitional cell carcinoma, n = 20 40% 80% N/A 40%
mammary adenocarcinoma, n = 20 0% 80% N/A 0%
squamous cell carcinoma, n = 10 0% 100% N/A 0%
thymic lymphoma, n = 10 90% 70% N/A 70%
rhabdomyosarcoma, n = 10 80% 50% N/A 40%
osteosarcoma, n = 10 80% 60% N/A 40%
myelogenous leukemia, n = 5 80% 100% N/A 80%
p53+/−;p73+/− thymic lymphoma, n = 10 90% N/A 80% 80%
hepatocellular carcinoma, n = 10 0% N/A 90% 0%
acinar pancreatic carcinoma, n = 10 0% N/A 90% 0%
rhabdomyosarcoma, n = 5 80% N/A 20% 20%
osteosarcoma, n = 10 80% N/A 70% 50%
p63+/−;p73+/− mammary adenocarcinoma, n = 10 N/A 90% 90% 90%
lung adenocarcinoma, n = 10 N/A 80% 90% 80%
thymic lymphoma, n = 10 N/A 70% 80% 70%
squamous cell carcinoma, n = 15 N/A 100% 0% 0%
myelogenous leukemia, n = 4 N/A 100% 50% 50%
N/A, not applicable; LOH, loss of heterozygosity; n, number of tumors analyzed; %, tumors with LOH.In a two-year aging study, these mice were found to have a
shorter life span than wild-type, p63+/−, or p73+/− mice (Figure
1). The median survival age for these compound heterozygotes
was 8 months, which is similar to the median survival age of
p53+/− mice (10 months), compared to 14 and 15 months for
p73+/− and p63+/− mice, respectively (Figure 1). Statistical
analysis using a log-rank test revealed that the difference in the
median survival age between the p63+/−;p73+/− mice and the
p63 and p73 single heterozygotes is statistically significant (p =
0.0001). p63+/−;p73+/− mice that died by 6 months of age had
developed thymic lymphoma, hemangiosarcoma, or myeloge-
nous leukemia (Figure 3C). For mice that died between 6 and
12 months of age, carcinomas were most prevalent: mammary
adenocarcinomas, lung adenocarcinomas, and squamous cell
carcinomas (Table 1 and Figures 3A, 3B, and 3D). Many of
these tumor types (including myelogenous leukemia, lung ade-
nocarcinomas, squamous cell carcinomas, and mammary ade-
nocarcinomas) were not detected in the p53+/− mice (Table 1),
suggesting different sites of action for p63 and p73 in tumor
suppression. Strikingly, the tumor types detected in the mice
are precisely those that have been shown to lose expression
of p63 and/or p73 in human tumors. These include transitional
cell carcinomas of the bladder (Koga et al., 2003; Park et al.,
2000; Puig et al., 2003; Urist et al., 2002), mammary adenocar-
cinomas (Ahomadegbe et al., 2000; Wang et al., 2002; Yama-
moto et al., 2002), osteosarcomas (Park et al., 2004), and my-
elogenous leukemia (Inokuchi et al., 2001; Yamaguchi et al.,
2001). In fact, a mutation in p63 and abnormalities in p73 that
are associated with myelogenous leukemia have been found
(Inokuchi et al., 2001; Yamaguchi et al., 2001). Interestingly,36610% of p63+/−;p73+/− mice develop myelogenous leukemia,
providing a suitable mouse model in which to study the dis-
ease. In addition to malignant lesions, some p63+/−;p73+/−
mice also developed benign or borderline malignant lesions,
including lung adenomas, salivary adenomas, and squamous
cell hyperplasia of various grades (Table 1).
Tumors from p63+/−;p73+/− mice exhibit LOH
The tumors from p63+/−;p73+/− mice exhibited loss of either
wild-type p63 or p73 or, in many cases, both genes. For exam-
ple, in 9 of 10 mammary adenocarcinomas from these mice,
loss of both p63 and p73 was detected (Table 2 and Figures
2B and 2D [T11]). A similar pattern was observed for lung ade-
nocarcinomas and thymic lymphomas (Table 2). Additionally,
half of the myelogenous leukemia cases in p63+/−;p73+/− mice
lost both p63 and p73. In contrast, all 15 of the squamous cell
carcinomas assayed from p63+/−;p73+/− mice selectively lost
the wild-type allele of p63 (Table 2). Thus, p63 and p73 partici-
pate in tumor suppression in tissues distinct from that of p53,
and the combination of the loss of p63 and p73 accelerates
tumorigenesis. It was striking that some of the prevalent tumor
types detected in the double mutant mice were mammary ade-
nocarcinomas and myelogenous leukemia. These are the tu-
mor types in humans that show loss or downregulation of p63
and/or p73 (Ahomadegbe et al., 2000; Inokuchi et al., 2001;
Moll, 2003; Park et al., 2000; Park et al., 2004; Puig et al., 2003;
Urist et al., 2002; Wang et al., 2002; Yamaguchi et al., 2001;
Yamamoto et al., 2002). In fact, the study of human myeloge-
nous leukemias identified a mutation in p63 associated with
the blast crisis of the disease in 12% of cases analyzed, indi-CANCER CELL : APRIL 2005
A R T I C L EFigure 2. Representative examples of LOH
analyses and immunohistochemistry (IHC) on tis-
sue samples from mice mutant for the p53 fam-
ily members
LOH of the gene assayed is indicated to the left
of each blot or gel. The genotypes of the mice
from which the tumors were derived are written
below each blot or gel: p53+/−;p63+/− (5/6),
p63+/−;p73+/− (6/7), p63+/− (6), p53+/−;p73+/− (5/7),
p73+/− (7).
A: Southern blot analysis for LOH of p63 from
macroscopic or laser capture microdissected
normal (N) and tumor (T) tissue of thymic lym-
phomas from p53+/−;p63+/− (N1, T1, T2) and
p63+/−;p73+/− mice (N3, T3) and mammary ade-
nocarcinomas from p53+/−;p63+/− (N4, T4) and
p63+/−;p73+/− mice (N5, T5).
B: PCR for p63 from squamous cell carcinomas
(SCC) from p53+/−;p63+/− (N6, T6) and p63+/−
mice (T7) and transitional cell carcinomas (TCC)
(N8, T8, T9) from p53+/−;p63+/− mice. Lung tumor
from p73+/− (T10) mouse and mammary adeno-
carcinoma from p63+/−;p73+/− (N11, T11) mouse.
C: PCR for p53 from thymic lymphoma from
p53+/−;p63+/− mice (N1, T1) and from a p53+/−;
p73+/− mouse (T12). TCC (N8, T8, T9), SCC (N6,
T6, T13), and mammary adenocarcinomas (N4,
T4, T14) from p53+/−;p63+/− mice.
D: PCR for p73 from a lung adenocarcinoma
(T10, N10) from a p73+/− mouse and mammary
adenocarcinomas (N5, T5, T11, T15), and SCC
(T16) from p63+/−;p73+/− mice.
E: IHC using an anti-p63 antibody on a mammary
adenocarcinoma that has undergone LOH for
both p63 and p73 from a p63+/−;p73+/− mouse.
F: IHC using an anti Np63 antibody on a mam-
mary adenocarcinoma from a p53+/−;p63+/−
mouse. The genotype of the tumor is p53+/−;
p63+/−.
G: IHC using an anti TAp63 antibody on a mam-
mary adenocarcinoma from a p53+/−;p63+/−
mouse. The genotype of the tumor is p53+/−;
p63+/−.
H: IHC using an anti-p63 antibody on the nor-
mal epithelium lining the bladder in a p53+/−;
p63+/− mouse.
I: IHC using an anti-Np63 antibody on a transitional cell carcinoma (TCC) of the bladder from a p53+/−;p63+/− mouse. The genotype of the tumor is p53+/−;
p63+/−.
J: IHC using an anti-TAp63 antibody on a transitional cell carcinoma (TCC) of the bladder from a p53+/−;p63+/− mouse. The genotype of the tumor is p53+/−;
p63+/−.
Arrows in F, H, and I point to positive nuclei shown in purple. Methyl green was used as a counterstain.cating again a correlation between the human and mouse data
(Yamaguchi et al., 2001).
Mice mutant for p63 or p73 in combination with p53
mutation lead to a more aggressive tumor phenotype
Given that p63 and p73 participate in tumor suppression, we
next examined whether they might genetically interact with p53
in tumor formation. Therefore, p63+/− and p73+/− mice were in-
tercrossed with p53+/− mice to obtain mice heterozygous for
mutations in both p53 and p63 (p53+/−;p63+/−) and for both p53
and p73 (p53+/−;p73+/−). As shown in Figure 1, p53+/−;p63+/−
and p53+/−;p73+/− cohorts (n = 40 mice each) had a shorter life
span than the p53+/− mice. The median age of survival of the
p53+/−;p63+/− and p53+/−;p73+/− mice was 7 and 6 months,
respectively, compared to 10 months for p53+/− mice. This dif-
ference was found to be statistically significant using a logrankCANCER CELL : APRIL 2005test (p = 0.001 and p = 0.0004, respectively). The shortened
life span in the compound mutants is most likely explained by
increased tumor burden and more extensive metastatic dis-
ease in these animals. While the p53+/− mice developed pri-
marily thymic lymphomas and sarcomas of various kinds, the
p53+/−;p63+/− mice developed squamous cell carcinomas with
high frequency (50%) in multiple tissues (larynx, pharynx, cer-
vix, and esophagus) (Figure 3E), transitional cell carcinoma of
the bladder (20%), and mammary adenocarcinomas (10%) (Ta-
ble 1, Figure 3F). These mice also developed some of the tu-
mors commonly observed in the p53+/− mice, such as thymic
lymphomas (10%), osteosarcomas (20%), and rhabdomysar-
comas (20%) (Table 1). Myelogenous leukemia was detected
in 15% of p53+/−;p63+/− mice, again indicating that p63 plays
an important role in this disease in mice and humans. The
p53+/−;p73+/− mice also displayed a distinct tumor spectrum367
A R T I C L EFigure 3. Examples of macroscopic and hema-
toxylin and eosin (H&E)-stained cross-sections of
tumors found in mice mutant for the p53 family
members
A: Mammary adenocarcinoma found on nec-
ropsy in a p63+/−;p73+/− mouse. Tumor is circled.
B: H&E-stained cross-sections of mammary ade-
nocarcinoma shown in A.
C: Thymic lymphoma from a p63+/−;p73+/− mouse.
D: Lung adenocarcinoma from a p63+/−;p73+/−
mouse.
E: Squamous cell carcinoma from a p53+/−;
p63+/− mouse.
F: Transitional cell carcinoma from a p53+/−;
p63+/− mouse.from p53+/− mice. The unique tumors detected in these mice
included acinar pancreatic carcinoma (15%), hepatocellular
carcinomas (15%), and lung adenocarcinomas (10%) (Table 1).
Additionally, p53+/−;p73+/− mice developed thymic lymphoma
(22.5%) and sarcomas (50%) as detected in the p53+/− mice
(Table 1).
p53+/−;p63+/− and p53+/−;p73+/− mice developed metastatic
tumors at a strikingly high frequency and a higher tumor bur-
den than p53+/− mice (Figure 4). Metastatic tumors were distin-
guished from primary tumors based on histology and tumor
location. The compound mutants developed metastatic dis-
ease at a frequency of 50% (p53+/−;p63+/−) and 45% (p53+/−;
p73+/−) compared to 5% of p53+/− mice (Figure 4C). 30% of
p63+/−;p73+/− developed metastatic disease as well (Figure3684C). The metastatic tumor types included squamous cell carci-
nomas that metastasized to the heart and lung (Figure 4A) and
osteosarcomas and rhabdomyosarcomas that metastasized to
the lung and liver (Figure 4B and data not shown). Many of the
lung adenocarcinomas in p53+/−;p73+/− and p63+/−;p73+/− mice
metastasized to the lymph nodes. To more clearly quantify and
compare the frequency of metastasis in mice from the various
genotypes compared to p53+/− mice, two tumor types that
were most prevalent and common among the genotypes were
analyzed. These were osteosarcomas and rhabdomyosarco-
mas. For osteosarcomas, 7 of 8 were metastatic in p53+/−;
p63+/− mice, 7 out of 8 in p53+/−;p73+/− mice, and 4 out of 8 in
p63+/−;p73+/− mice, compared to only 1 out of 8 in p53+/− mice
(Figure 4E). For rhabdomyosarcomas, 7 of 8 were metastaticCANCER CELL : APRIL 2005
A R T I C L EFigure 4. p53+/−;p63+/−, p53+/−;p73+/−, and p63+/−;
p73+/− mice have high tumor burden and tu-
mors that are highly metastatic
A: Squamous cell carcinoma of the esophagus
that has metastasized to the lung from a p63+/−;
p73+/− mouse.
B: Osteosarcoma from a p53+/−;p73+/− mouse
that has metastasized to the liver.
C: Percent mice with metastatic tumors.
D: Percent mice with multiple tumors.
E: Percent mice with metastatic osteosarcomas.
F: Percent mice with metastatic rhabdomyosar-
comas.in p53+/−;p63+/− mice, 7 out of 8 for p53+/−;p73+/− mice, and 6
out of 8 for p63+/−;p73+/− mice, compared to 0 out of 8 for
p53+/− mice (Figure 4F). These results were found to be statis-
tically significant using a χ2 test. For osteosarcomas, p53+/−;
p63+/− and p53+/−;p73+/− mice had a p value of .01 and p63+/−;
p73+/− mice had a p value of 0.025. For rhabdomyosarcomas,
p53+/−;p63+/−, p53+/−;p73+/−, and p63+/−;p73+/− mice had a p
value of .01. Interestingly, data from human tumors has indi-
cated that p63 and p73 may play a role in progression, as their
loss is seen in higher-grade tumors (Koga et al., 2003; Park et
al., 2000; Park et al., 2004; Urist et al., 2002; Wang et al., 2002;
Yamamoto et al., 2002). Data from the mice shows that loss of
p63 and p73 leads to more aggressive disease.
These compound mutants also exhibited an increase in tu-
mor burden (Figure 4D). 90% of p53+/−;p63+/−, 75% of p53+/−;
p73+/−, and 50% of p63+/−;p73+/− mice had multiple tumors of
the same or distinct types compared to only 10% of p53+/−
mice (n = 40) (Figure 4D). For example, many of the p63+/−;
p73+/− mice with mammary adenocarcinomas had multipleCANCER CELL : APRIL 2005lesions within multiple mammary glands of a single mouse. The
p53+/−;p63+/− mice developed collision tumors composed of
mammary adenocarcinomas directly adjacent to squamous
cell carcinomas and/or rhabdomysarcomas. These data indi-
cate that p63 and p73 contribute to tumor suppression, and
that loss of these genes increases the severity of disease on
the p53+/− background.
Mice mutant for p53 and p63 or p53 and p73 exhibit LOH
of one or both genes
LOH in tumors from p53+/−;p63+/− and p53+/−;p73+/− mice was
also examined using the techniques described previously (n =
10 or 20 for each tumor type). Certain tumor types in p53+/−;
p63+/− mice underwent loss of p63 at a higher frequency than
loss of p53, including the transitional cell carcinomas (40% for
p53, 80% for p63, 40% for both) (Figures 2B and 2C [T8 and
T9]), mammary adenocarcinomas (0% for p53 and 80% for
p63) (Figures 2A and 2C [T4]), squamous cell carcinomas (0%
for p53 and 100% for p63) (Figures 2B and 2C [T6]), and my-369
A R T I C L Eelogenous leukemias (80% for p53, 100% for p63, 80% for
both) (Table 2). Other tumor types in these animals showed the
opposite pattern. For example, 80% of rhabdomyosarcomas
had p53 LOH, while only 50% showed LOH for p63. Examina-
tion of tumors from p53+/−;p73+/− mice revealed LOH of p73 in
90% of hepatocellular carcinomas and 90% of acinar pancre-
atic carcinomas, while LOH of p53 was not detected in these
tumors (Table 2). These data indicate that the tumor-suppres-
sive function of the p53 family members seems to be tissue-
specific, and imply that there is differential selection pressure
for their inactivation.
Transitional cell carcinoma (TCC) and mammary
adenocarcinoma selectively lose expression of TAp63
Many recent reports have shown the loss of expression of p63
and p73 in various human tumors, including malignant mam-
mary adenocarcinomas (Ahomadegbe et al., 2000; Wang et al.,
2002; Yamamoto et al., 2002), bladder adenocarcinomas (Koga
et al., 2003; Park et al., 2000; Puig et al., 2003; Urist et al.,
2002), osteosarcomas (Park et al., 2004), myelogenous leuke-
mia (Inokuchi et al., 2001; Yamaguchi et al., 2001), and buccal
carcinomas (Chen et al., 2004b; Chen et al., 2004c). To deter-
mine whether loss of expression of p63 occurs in the tumors
from p53+/−;p63+/− and p63+/−;p73+/− mice, immunohisto-
chemistry was performed using an antibody for p63. p63 was
clearly detectable in the basal layer of the epithelium in mam-
mary ducts and in the epithelial lining of the bladder (Figure 2H
and data not shown); however, the mammary tumors with LOH
not surprisingly lost expression of p63 (Figure 2E). A subset of
mammary adenocarcinomas and transitional cell carcinomas
from p53+/−;p63+/− mice did not exhibit LOH (Table 2, n = 4
tumors each) of p63. These tumors were histologically less ag-
gressive than those that lost the remaining wild-type allele of
p63. These tumors were analyzed using isoform-specific anti-
bodies for TA versus N p63 to determine whether a similar
pattern of p63 isoform expression is seen in mouse and human
tumors. Indeed, these tumors exhibited a loss of expression
of specifically the TAp63 isoforms (Figures 2G and 2J), while
retaining expression of the N variants (Figures 2F and 2I), as
has been reported for these tumor types in human patients
(Park et al., 2000). This result indicates that loss of p63 and
perhaps more specifically loss of TAp63 is important for the
progression of some types of mammary adenocarcinomas and
transitional cell carcinomas. These data also indicate that
these mouse models mimic the human condition and may be
a suitable system to study mechanisms of tumorigenesis and
the effects of cancer therapies.
Mice mutant for p63 exhibit signs of advanced aging
In addition to the development of spontaneous tumors, mice
mutant for p63 also showed increased signs of aging (Figure
5). These mice developed severe degenerative disc disease of
the spine at ages ranging between 6 and 18 months of age
(Figures 5B and 5D). The degenerative disc disease was most
consistent with spondylosis and was most frequently detected
in the cervical and thoracic regions. All groups of mice hetero-
zygous for the p63mutation exhibited this phenotype with high
frequency (p63+/− = 40%, p53+/−;p63+/− = 40%, and p63+/−;
p73+/− = 60%). None of the p53+/− or wild-type mice develop
these disease symptoms, and only a small percentage of p73+/−
or p53+/−;p73+/− mice were affected. In 10% of p63+/−;p73+/−370mice, the degenerative disc disease was so severe that it re-
sulted in partial paralysis.
Discussion
p63 and p73 were cloned due to their structural similarity to
p53 and have been shown to share some functions with this
well-studied tumor suppressor gene, but their own contribu-
tions to the inhibition of tumor formation has been uncertain.
Indeed, there has been much debate and speculation about
the possible roles of p63 and p73 in tumor suppression. Many
studies have revealed p53-like functions of p63 and p73, such
as their ability to induce apoptosis, suggesting that they may
play a role in tumor suppression, yet initial studies indicated
that p63 and p73 were not frequently mutated in human can-
cers (Hagiwara et al., 1999; Irwin and Kaelin, 2001). Many of
these studies focused on the DNA binding domain and may
have missed mutations in other regions of the genes or on spe-
cific isoforms of p63 or p73 (Hagiwara et al., 1999; Hibi et al.,
2000; Ng et al., 2000). The study of p63 and p73 has also been
hampered by the existence of multiple isoforms with opposing
activities. Some reports have shown that the N isoforms are
overexpressed in certain malignancies and may have onco-
genic potential (Concin et al., 2004; Zaika et al., 2002). How-
ever, recent analyses of human tumors have shown the loss of
expression of p63 and/or p73 in many tumors, including transi-
tional cell carcinomas, mammary adenocarcinomas, and squa-
mous cell carcinomas (Ahomadegbe et al., 2000; Chen et al.,
2004a; Chen et al., 2003; Koga et al., 2003; Moll, 2003; Park
et al., 2000; Park et al., 2004; Puig et al., 2003; Urist et al.,
2002), indicating that these genes have tumor-suppressive
activities. The present study provides direct evidence that p63
and p73 play a role in tumor suppression, and several impor-
tant conclusions can be drawn from these data. p63 and p73
are by themselves tumor suppressor genes, and are more po-
tent when deleted in combination. Additionally, loss of p63 and
p73 can cooperate with p53 in tumor suppression. These ob-
servations correlate with data from specific human tumors. The
most prevalent tumor types in mice mutant for p63 and p73
are those that have been found to lose expression of p63 or
p73 in human tumors.
Previous reports on the mice mutant for p63 and p73 seem-
ingly contradict the data reported here. However, tumors de-
tected in p63+/− and p73+/− mice in this study were evident,
starting at approximately 12 months of age. Most of these tu-
mors were small and not grossly apparent. Analysis of these
mice required a full necropsy of each mouse at the time of
death and careful examination by a mouse pathologist. Addi-
tionally, analysis of compound p53 family crosses had not been
performed previously, and the data from these studies show
that in combination with each other or with p53, p63 and p73
are potent tumor suppressor genes.
There is accumulating evidence from human tumors that p63
and p73 play a role in tumor suppression. Some human tumor
types have been shown to lose expression of p63 and p73,
supporting a role for these genes in tumor suppression. Inter-
estingly, multiple studies have shown that loss of p63 expres-
sion is associated with tumor progression and poor prognosis
in human bladder cancers (Koga et al., 2003; Park et al., 2000;
Urist et al., 2002). Bladder tumors were prevalent in p53+/−;
p63+/− mice, and these tumors also exhibited loss of p63 ex-CANCER CELL : APRIL 2005
A R T I C L EFigure 5. Mice mutant for p63 exhibit early signs
of aging
A: p63+/−;p73+/ mouse at 6 months of age with
a hunched appearance.
B: Hematoxylin and eosin stained cross-section
of the spine of a 6-month-old p63+/−;p73+/−
mouse with degenerative disc disease.
C: Percentage of mice for each genotype with
disc disease at 10 months of age.
D: Higher magnification of B.pression through LOH. Moreover, we observed that the few
transitional cell carcinomas and mammary adenocarcinomas
that did not exhibit LOH of p63 selectively lost expression of
TAp63 and not Np63, indicating that loss of TAp63 may be
an important event in the development of transitional cell carci-
noma and mammary adenocarcinoma. This pattern of expres-
sion has been detected in transitional cell carcinomas in hu-
mans (Park et al., 2000). Likewise, LOH, allele silencing, and
decreased expression of p73 and p63 have been detected in
breast cancers (Ahomadegbe et al., 2000; Wang et al., 2002;
Yamamoto et al., 2002). The mammary adenocarcinomas from
the p63+/−;p73+/− mice also exhibited LOH for both p63 and
p73. Another important piece of evidence tying p63 and p73
to human tumor suppression is a mutation in p63 that has been
identified in 12% of chronic myelogenous leukemia cases. Two
groups of mice that harbor p63 mutations (p53+/−;p63+/− and
p63+/−;p73+/−) developed myelogenous leukemia.
The tumor-suppressive activities of p63 and p73 seem to
play an important role in specific tissues. Based on the tumor
spectrum of p63 and p73 mutant mice, these genes seem to
have unique sites of action. The tumor spectrum detected in
mice mutant for p63 and p73 is quite different from that of
p53-deficient mice (Jacks et al., 1994). These p53 mutant mice
primarily develop thymic lymphomas and sarcomas. In con-
trast, p63 and p73 mutant mice develop primarily carcinomas
and fewer sarcomas. This is most likely due to the pattern of
expression of p63 and p73. While p53 is ubiquitously ex-
pressed, p63 and p73 are highly expressed in epithelial tissues,
the site of carcinoma development. Additionally, loss of p63 or
p73 in combination with p53 led to a more severe and aggres-
sive tumor phenotype. Compound p53/p63 and p53/p73 mu-
tant mice displayed high tumor burden and highly metastatic
disease. Earlier work had revealed that cells lacking both p53
and p63 (p53−/−;p63−/−) and p53 and p73 (p53−/−;p73−/−) were
more resistant to the induction of apoptosis by DNA damagingCANCER CELL : APRIL 2005agents than cells lacking just p53 (p53−/−) (Flores et al., 2002).
These data indicated that p63 and p73 have antiapoptotic
functions that are independent of p53. The tumor data from the
p53/p63 and p53/p73 mice correlate with the earlier data and
show that p63 and p73 have functions independent of p53 that
lead to more aggressive tumor phenotypes in the compound
mutant mice. The data from human tumors, such as in transi-
tional cell carcinoma, also indicate that loss of p63 and p73
are indicators of more aggressive tumors and those with poor
clinical prognosis (Koga et al., 2003; Park et al., 2000; Urist et
al., 2002).
Many possible mechanisms for p63 and p73’s role in tumor
suppression exist, including the dependence of p53 on p63
and p73 to induce apoptosis in certain tissues (Flores et al.,
2002). This does not hold true in all tissues, because combined
mutation of p63 and p73 does not affect p53-dependent apo-
ptosis in thymocytes (Senoo et al., 2004). However, the p63/
p73 compound mutant mice develop thymic lymphomas, indi-
cating that apoptosis may not be the primary mechanism of
action for tumor suppression in this tissue. Another mechanism
of p63 and p73’s tumor suppressive activities could be through
the known inhibition of these genes by point mutant p53, a
common mutation in human tumors (Di Como et al., 1999;
Gaiddon et al., 2001). Numerous cell-based and biochemical
studies have shown that point mutant p53 can associate with
and inhibit the transcriptional activation of p63 and p73 on vari-
ous target genes such as p21, an important cell cycle regulator
(Di Como et al., 1999; Gaiddon et al., 2001; Irwin et al., 2003;
Strano and Blandino, 2003; Strano et al., 2002). This transdom-
inant negative regulation could account for the promotion of
tumorigenesis by tumor-derived point mutants of p53, and may
explain the low frequency of mutations detected in p63 and
p73 in human tumors, providing another possible mechanism
of action. Additionally, recent in vivo data indicates that mice
carrying point mutant p53 exhibit a similar tumor spectrum,371
A R T I C L Etumor burden, and rate of metastasis to the compound p53/
p63 and p53/p73 mutant mice in this study (Lang et al., 2004;
Olive et al., 2004).
In addition to the tumor phenotype detected in mice mutant
for p63 and p73, these mice developed signs of premature
aging. This phenotype was most severe in the p63+/−;p73+/−
mice. The p63−/− mice were reported to have bone defects:
craniofacial abnormalities and defects in limb development
(Mills et al., 1999; Yang et al., 1999). Although the exact mech-
anism for the disc disease in these mice is not known, it is
possible that a gene dosage effect in the p63+/− mice could
account for bone defects in the adult mouse.
The study of p63 and p73 in tumor suppression is indeed
complex. Some tumors have been shown to upregulate the N
isoforms while downregulating the TA isoforms (Zaika et al.,
2002), while other studies have shown exactly the opposite
(Park et al., 2000). The data to date is so complex and puzzling
that no clear conclusion can be drawn about the definitive
function of each isoform at this time. These opposing data sets
most likely reflect tissue specificity of the various isoforms of
p63 and p73. The future generation of isoform-specific knock-
out mice will likely shed much-needed light on the activities of
the various p63 and p73 isoforms in various tissues and cellu-
lar processes. Even so, the data presented here clearly show
that loss of function of p63 or p73 leads to tumor development.
This may have important implications for the treatment of cer-
tain cancers, particularly those that retain wild-type p53 and
exhibit loss or mutation of p63 or p73 or those that carry point
mutant alleles of p53. Tumors that arise in these mice (or cells
derived from them) should be helpful in determining what ther-
apeutic strategies might be most useful in human cancers that
arise through mutation or functional inactivation of the broader
p53 family.
Experimental procedures
Mouse husbandry and tumor analysis
Mice double heterozygous for the p53 family members (p53+/−;p63+/−, p53+/−;
p73+/−, and p63+/−;p73+/−) on a mixed C57BL/6 × 129/SvJae background
were backcrossed to C57BL/6 for four generations to enrich for the C57BL/6
background. The published p63+/− and p73+/− mice were on a mixed
(C57BL/6 × 129/SvJae) background. Resulting mice were intercrossed to
generate the mice (wild-type, p53+/−, p63+/−, p73+/− p53+/−;p63+/−, p53+/−;
p73+/−, and p63+/−;p73+/−) for the study. Mice were aged until moribund for
up to 24 months. Ill and distressed mice were euthanized by asphyxiation
using carbon dioxide following the guidelines of the IACUC. Necropsies
were performed and soft tissue organs were fixed in 10% neutral buffered
formalin, and bones were placed in Bouin's fixative for 3 weeks. Fixed tis-
sues were embedded in paraffin and sectioned onto slides. Slides were
stained with hematoxylin and eosin. Histopathological analysis for each or-
gan was performed.
Immunohistochemistry
Sections from paraffin-embedded tissue were dewaxed with xylene and
rehydrated in a graded series of ethanol following standard protocols.
Slides were incubated with primary antibody (clone 4A4, F. McKeon) that
detects multiple isoforms of p63, or the TAp63-specific antibody (D20,
Santa Cruz) or Np63-specific antibody (N16, Santa Cruz) at a dilution of
1:100 for 12 to 15 hr at 4°C. For detection, the Vectastain Kit (Vector Labs)
was used, followed by the VIP kit (Vector Labs), and counterstained with
methyl green (Vector Labs).
Analysis for LOH of p63 and p73
For macroscopic tumors, samples were taken from fresh tumor tissue and
adjacent normal tissue at the time of necropsy. Genomic DNA was ex-372tracted from the tissue using DNAzol reagent (GibcoBRL). For detection of
p63, the genomic DNA was digested with Bgl1 and BamHI, electrophoresed
on a 0.8% agarose gel, and transferred to Hybond N+ membrane (Amer-
sham) using standard Southern blotting techniques. Blots were probed with
a radiolabeled fragment of genomic p63 DNA. Probes were prepared by
digesting genomic p63 DNA with BamHI and NheI and by radiolabeling with
the Prime-It II kit (Stratagene) and [α-32P]dATP. The 13 kb band corresponds
to the wild-type allele and the 7.5 kb band to the mutant allele of p63.
Microscopic tumors were microdissected by laser capture (Arcturus II) from
10 M paraffin sections on uncoated glass slides. DNA was prepared from
captured samples by overnight digestion at 37°C in 100 µl of LCM buffer
(pH 8.0) (0.04% proteinase K, 10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 1%
Tween 20). Proteinase K was inactivated by heating to 95°C for 8 min. PCR
was performed for p53, p63, or p73 as described previously (Jacks et al.,
1994; Yang et al., 1999; Yang et al., 2000).
Quantification of tumor burden and metastases
Histopathology of hematoxylin and eosin stained slides was performed on
every soft tissue organ and bone for each mouse. Mice with more than two
tumors were scored as containing multiple tumors. When multiple tumors
were detected in the same organ, serial sectioning of the organ was done
to ensure that the two lesions were not part of one contiguous lesion. Mice
with metastases of the primary tumor in a lymph node or distant organ were
scored as having metastatic disease. Metastases were distinguished from
primary tumors by histopathology.
Statistical analysis
χ2 test using Microsoft Excel was performed on metastatic osteosarcomas
and rhabdomyosarcomas from p53+/−;p63+/−, p53+/−;p73+/−, and p63+/−;
p73+/− mice compared to metastatic osteosarcomas and rhabdomyosarco-
mas from p53+/− mice. Survival curves were generated using mice that were
euthanized when moribund. The logrank (Mantel-Haenszel) test was used
to calculate statistical significance (PRISM4, GraphPad).
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